Phase 3
N=7,466
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
Cervical Cancer · Precancerous Condition
Bottom Line
View on ClinicalTrials.gov: NCT00128661 ↗Enrolled (actual)
7,466
Serious AEs
24.2%
Results posted
May 2012
Primary outcome: Primary: Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen. — 1; 9; 0; 2 Events
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine (Biological); hepatitis A inactivated virus vaccine (Biological)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- GlaxoSmithKline
- Primary completion
- Dec 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen. |
1; 9; 0; 2; 1; 10 | — |
| SECONDARY Number of Cervical Infection With HPV16 or HPV18. |
13; 77; 10; 57; 22; 118 | — |
| SECONDARY Number of Histopathologically Confirmed CIN2+ Cases Associated With Infection by Any Oncogenic HPV Type |
1; 9; 0; 2; 1; 6 | — |
| SECONDARY Number of Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 Cases |
10; 71; 0; 37; 10; 104 | — |
| SECONDARY Geometric Mean Titers (GMTs) for HPV-16 Antibody in the Immunogenicity Subcohort. |
6.7; 8.2; 646.6; 7.9; 771.5; 8.4 | — |
| SECONDARY Geometric Mean Titers (GMTs) for HPV-18 Antibody in the Immunogenicity Subcohort |
5.4; 6.2; 372.7; 6.4; 532.2; 6.7 | — |
| SECONDARY HPV-16 Geometric Mean Titers (GMTs) (V5 Monoclonal Antibody Inhibition Test) |
21.1; 21.4; 58.5; 21.5; 80.9; 21.5 | — |
| SECONDARY HPV-18 Geometric Mean Titers (GMTs) (J4 Monoclonal Antibody Inhibition Test) |
55.0; 55.7; 99.1; 55.3; 111.4; 55.4 | — |
| SECONDARY Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. |
1627; 1610; 25; 20; 544; 501 | — |
| SECONDARY Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms. |
512; 502; 6; 5; 257; 232 | — |
| SECONDARY Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms on a 10% Random Subset of Participants. |
202; 74; 0; 0; 6; 1 | — |
| SECONDARY Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms on a 10% Random Subset of Participants. |
214; 189; 2; 0; 250; 211 | — |
| SECONDARY Number of Subjects Reporting Serious Adverse Events (SAEs). |
912; 891 | — |
| SECONDARY Number of Subjects Reporting Unsolicited Adverse Events (AEs). |
1638; 1536 | — |
| SECONDARY Number of Subjects With All Possible Pregnancy Outcomes |
317; 294; 1756; 1766; 50; 69 | — |
| SECONDARY Number of Cervical Infection With HPV16 or HPV18. |
13; 77; 10; 57; 22; 118 | — |
| SECONDARY Number of Cervical Infection With HPV16 or HPV18. |
13; 77; 10; 57; 22; 118 | — |
| SECONDARY Number of Cervical Infection With HPV16 or HPV18. |
13; 77; 10; 57; 22; 118 | — |
| SECONDARY Number of Cervical Infection With HPV16 or HPV18. |
13; 77; 10; 57; 22; 118 | — |
| SECONDARY Number of Subjects Reporting Unsolicited Adverse Events (AEs). |
1638; 1536 | — |
Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in preventing cervical intraepithelial neoplasia or cervical cancer. It is not yet known whether human papillomavirus vaccine is more effective than hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer.
PURPOSE: This randomized phase III trial is studying human papillomavirus vaccine to see how well it works compared to hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer in younger healthy participants.
Eligibility Criteria
DISEASE CHARACTERISTICS:
•Healthy participants
- Deemed to be in good general health by history and physical examination
•Resident of Guanacaste Province of Costa Rica and surrounding areas
- Must remain a resident for ≥ 6 months after the first study vaccination
PATIENT CHARACTERISTICS:
Age
- 18 to 25
Performance status
•Not specified
Life expectancy
•Not specified
Hematopoietic
•Not specified
Hepatic
- No history of chronic hepatitis requiring treatment
- No acute or chronic clinically significant hepatic function abnormality by physical examination or laboratory findings
- No known history of hepatitis A infection
Renal
- No history of kidney disease requiring treatment
- No acute or chronic clinically significant kidney function abnormality by physical examination or laboratory findings
Cardiovascular
- No acute or chronic clinically significant cardiovascular function abnormality by physical examination or laboratory findings Pulmonary
- No acute or chronic clinically significant pulmonary function abnormality by physical examination or laboratory findings Immunology
- No history of allergic disease
- No history of autoimmune disorder requiring treatment
- No history of allergic reaction (e.g., difficulty breathing) to any vaccine
- No suspected allergy or reaction likely to be exacerbated by a component of the study vaccines (e.g., 2-phenoxyethanol or neomycin)
- No hypersensitivity to latex
- No diagnosis or suspicion of any immunodeficient condition by medical history or physical examination Other
- Not pregnant or nursing
◦No delivery within the past 3 months
- Negative pregnancy test
- Fertile patients must use effective contraception for 30 days before, during, and for 60 days after completion of study treatment
- Able to speak or understand Spanish
- Mentally competent
- Able to undergo pelvic exam (i.e., no heavy bleeding [menstruation or otherwise] or heavy vaginal discharge)
- No history of cancer requiring treatment
- No history of diabetes requiring treatment
- No history of other chronic conditions requiring treatment
- No acute or chronic clinically significant neurologic function abnormality by physical examination or laboratory findings
- No other acute disease
- No fever ≥ 37.5º C
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 6 months since prior chronic administration (i.e., > 14 days) of immune-modulating drugs
- More than 90 days since prior immunoglobulins
- More than 30 days since prior and no other concurrent investigational or non-registered vaccines
- More than 30 days since prior registered vaccines
- More than 8 days since prior routine meningococcal, hepatitis B, influenza, or diphtheria/tetanus vaccine
- No prior vaccination against hepatitis A
- No prior vaccination against human papillomavirus
- No prior monophosphoryl lipid A or AS04 adjuvant
Chemotherapy
•Not specified
Endocrine therapy
- More than 6 months since prior chronic administration (i.e., > 14 days) of corticosteroids (e.g., ≥ 0.5 mg/kg/day of prednisone or equivalent)
- Concurrent inhaled or topical steroids allowed
Radiotherapy
•Not specified
Surgery
•No prior hysterectomy
Other
- More than 6 months since prior chronic administration (i.e., > 14 days) of immunosuppressants
- More than 30 days since prior and no other concurrent investigational or non-registered drugs
Data sourced from ClinicalTrials.gov (NCT00128661). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.